To systematically evaluate the efficacy and safety of the prescription for the treatment from liver on type 2 diabetic mellitus(T2DM).Methods:Databases including PubMed，EMbase，the Cochrane Library,Web of Science，WanFang，CNKI and SinoMed Data were searched by computer to collect randomized controlled trials(RCTs)on the prescription for the treatment of T2DM(Time limit：from inception to April 28th 2020).A total of 2 researchers screened，extracted the literature，and assessed the risk of bias.And then the statistical analysis was performed by using software RevMan5.3.Results:A total of 13 RCTs involving 1275 patients were adopted.The Meta-analysis results demonstrated that，compared with control group，the prescription of the treatment from liver on T2DM group was better in reducing glycosylated hemoglobin(HbA1c)(MD=-0.61，95%CI(-0.95，-0.27)，P=0.000 5)，fasting blood glucose(FBG)(MD=-0.90，95%CI=(-1.19，-0.61)，P<0.00001)，and improving body mass index(BMI)(MD=-0.80，95%CI=(-1.29，-0.32)，P=0.001)，and TCM syndrome scores(MD=-3.29，95% CI=(-4.36，-2.22)，P<0.00001).However，total cholesterol(TC)(MD=-0.22,95% CI=(-0.66，0.22)，P=0.33)，triglycerides(TG)(MD=-0.07，95%CI=(-0.39，0.26)，P=0.68)and adverse reactions.The differences were not statistically significant.Conclusion:Current evidence suggests that the prescription and drugs from liver treatment could decrease HbA1c and FBG，improve BMI and TCM syndrome scores，with good safety.However,on account of the situation of the included studies(quantity and quality)，more high quality studies and rigorous designed research are required to verify the above conclusions.